Evidence map›Paper›PMID 30008587›Full record

ReviewInternational journal of medical sciences2018

Hyperbaric Oxygen Therapy in Liver Diseases.

Yun Sun, Yankai Wen, Chanjuan Shen, Yuanrun Zhu, Wendong You, Yuanyuan Meng, Lijuan Chen, Yiping Feng, Xiaofeng Yang, Zuo-Bing Chen

Open access · goldAbstract readReview
In one paragraph

Review in International journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. [Protective effect and mechanism of hyperbaric oxygen therapy on non-alcoholic fatty liver disease in mice].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yun SunDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Yankai WenSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Chanjuan ShenDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Yuanrun ZhuDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Wendong YouDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Yuanyuan MengDepartment of Pediatric Medicine, The Children's Hospital, Zhejiang University, Hangzhou, China.
Lijuan ChenDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Yiping FengDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Xiaofeng YangDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Zuo-Bing ChenDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperbaric oxygen therapy (HBOT) is an efficient therapeutic option to improve progress of lots of diseases especially hypoxia-related injuries, and has been clinically established as a wide-used therapy for patients with carbon monoxide poisoning, decompression sickness, arterial gas embolism, problematic wound, and so on. In the liver, most studies positively evaluated HBOT as a potential therapeutic option for liver transplantation, acute liver injury, nonalcoholic steatohepatitis, fibrosis and cancer, especially for hepatic artery thrombosis. This might mainly attribute to the anti-oxidation and anti-inflammation of HBOT. However, some controversies are existed, possibly due to hyperbaric oxygen toxicity. This review summarizes the current understandings of the role of HBOT in liver diseases and hepatic regeneration. Future understanding of HBOT in clinical trials and its in-depth mechanisms may contribute to the development of this novel adjuvant strategy for clinical therapy of liver diseases.

Indexed as

Hyperbaric OxygenationHumansLiver DiseasesLiver Regenerationhyperbaric oxygenliver diseasestoxicity

Identifiers

PMID30008587
PMCPMC6036079
OpenAlexW2805566587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.